Engineering Inflammation‐Resistant Cartilage: Bridging Gene Therapy and Tissue Engineering

Abstract

AbstractArticular cartilage defects caused by traumatic injury rarely heal spontaneously and predispose into post‐traumatic osteoarthritis. In the current autologous cell‐based treatments the regenerative process is often hampered by the poor regenerative capacity of adult cells and the inflammatory state of the injured joint. The lack of ideal treatment options for cartilage injuries motivated the authors to tissue engineer a cartilage tissue which would be more resistant to inflammation. A clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 knockout of TGF‐β‐activated kinase 1 (TAK1) gene in polydactyly chondrocytes provides multivalent protection against the signals that activate the pro‐inflammatory and catabolic NF‐κB pathway. The TAK1‐KO chondrocytes encapsulate into a hyaluronan hydrogel deposit copious cartilage extracellular matrix proteins and facilitate integration onto native cartilage, even under proinflammatory conditions. Furthermore, when implanted in vivo, compared to WT fewer pro‐inflammatory M1 macrophages invade the cartilage, likely due to the lower levels of cytokines secreted by the TAK1‐KO polydactyly chondrocytes. The engineered cartilage thus represents a new paradigm‐shift for the creation of more potent and functional tissues for use in regenerative medicine.